IO Biotech CSO speaks at Cancer Biotherapeutics Conference

Jan 4, 2016

On 14-15 March 2016, London sets the scene for Cambridge Healthtech Institute’s Inaugural conference, Cancer Biotherapeutics, presenting new developments, in-depth discussions and focused short courses from academia and industry with a strong focus on immunotherapy.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial